CRISPR Therapeutics (CRSP) just reported one year durability data from its Phase 1a CTX310 trial, showing sustained reductions in ANGPTL3, triglycerides, and LDL after a single intravenous gene editing treatment.
The latest CTX310 readout lands after a softer trading patch, with the share price down 7.49% over the past week and 3.35% over 30 days. A 4.94% 90 day share price return contrasts with a weaker 1 year total shareholder return of 6.49% and a 5 year total shareholder loss of 55.49%, suggesting momentum has been tentative despite periodic bursts of optimism around CRISPR Therapeutics and its pipeline updates.
Scan beyond CRISPR Therapeutics and see how other potential breakout ideas stack up on quality, balance sheet strength, and valuation across our curated 18 high quality undiscovered gems
CRISPR Therapeutics now trades lower despite fresh CTX310 durability data, so the question shifts to price. Does today’s valuation still reward investors for taking on this gene editing risk profile?
Preferred Price to Book Multiple of 2.9x for CRISPR Therapeutics: Is It Justified?
CRISPR Therapeutics currently trades on a price to book, or P/B, ratio of 2.9x, which puts a concrete number on how much investors are paying relative to its net assets.
The P/B multiple compares the market value of the business to its book value, essentially asking how many dollars you are paying for each dollar of accounting equity. For pre profit biotech groups that rely heavily on clinical progress and future licensing or product cash flows, this ratio often reflects how much faith the market has in the pipeline beyond the current balance sheet.
Against a peer group benchmark of 11.4x mentioned in the data, the 2.9x preferred multiple is described as good value in one comparison, which indicates the broader group used for that check is priced much higher on a book basis. In a separate statement, the same 2.9x P/B is characterized as more expensive than the 2.4x average for the US Biotechs industry, which shows how sensitive the conclusion is to the reference set investors use when thinking about CRISPR Therapeutics.
That contrast means the same ratio can look modest when set against high multiple comparables and richer when stacked against a narrower biotech industry cut. The key question for readers is which peer yardstick feels more relevant for a company with CRISPR Therapeutics' size, pipeline mix, and current lack of profitability.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book of 2.9x (ABOUT RIGHT)
Still, the CRISPR Therapeutics story can break if CTX310 safety signals, regulatory pushback, or slower than expected CASGEVY adoption weaken confidence in future cash generation.
Find out about the key risks to this CRISPR Therapeutics narrative.
Another View on CRISPR Therapeutics Using Our DCF Model
The P/B discussion paints CRISPR Therapeutics as roughly fairly placed against different peer groups, yet our DCF model sends a very different signal. With the share price at $52.26 versus an SWS DCF value of $215.54, the stock screens as heavily undervalued on future cash flows.
That sort of gap can reflect genuine mispricing or simply very cautious expectations around execution, competitive pressure, and financing needs. The key question is which perspective appears more compelling: the balance sheet multiple or the forward looking cash flow math.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CRISPR Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 33 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Big valuation gaps like this rarely stay ignored for long, so it pays to look under the hood yourself and decide where you stand. To see what investors are currently optimistic about in CRISPR Therapeutics, review its 2 key rewards
Looking for more investment ideas beyond CRISPR Therapeutics?
Do not stop with CRISPR Therapeutics. The market keeps moving, and if you only watch one stock you risk missing opportunities that better fit your goals and risk appetite.
- Target potential value plays before the crowd catches on by scanning our 33 high quality undervalued stocks.
- Lock in income focused opportunities by reviewing a curated 6 dividend fortresses.
- Prioritise sleep at night holdings by filtering for a 11 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com